Hinge Health Inc. Class A Common Stock vs Toyota Motor Corp — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Toyota Motor Corp trades at $191.06 (market cap $221.69B). The key difference: Toyota Motor Corp is far larger — about 26.1× Hinge Health Inc. Class A Common Stock's market cap, and Toyota Motor Corp pays a 3.32% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Toyota Motor Corp for 116 Days on average.
| HNGE | TM | |
|---|---|---|
Market Cap | $8.48B | $221.69B |
Volume | 879,799 | 298,766 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.14 | $248.29 |
52-Week Low | $31.17 | $166.50 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $8.10B | $414.72B |
Dividend Yield | — | 3.32% |
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Toyota Motor trades at $188.60, up 2.1% with bearish technical signals but strong fundamentals. The stock shows attractive valuation with P/E of 8.5 and P/S of 0.74, supported by consistent earnings beats. Recent news highlights growing U.S. market share and electrification progress, though China sales remain a concern. Cash flow trends show recovery from 2025's negative position to projected $2.25T positive in 2026.
Toyota presents a value opportunity with solid profitability and market positioning, though technical weakness and China headwinds warrant caution. The 37.5% buy rating from analysts reflects divided sentiment despite strong fundamentals. Key catalysts include electrification expansion and U.S. market gains, while risks involve production disruptions and competitive pressures in key markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →